Heart Attack News and Research

RSS

HDL cholesterol can transform from good to bad actor in heart-disease process

We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of patients at high risk for recurrent coronary events, such as chest pain, heart attack, and death.

26 May 2010

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial.

25 May 2010

Researchers develop new device that can change current landscape of chronic wound management

Complex wounds affect more patients in the United States than heart attack and stroke combined, and five to seven million Americans with complex wounds account for over $20 billion in healthcare expenditures. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease.

25 May 2010

EHSI reports favorable completion of due diligence with Stand-By Systems

Emerging Healthcare Solutions, Inc. disclosed today that the Company has just favorably completed the financial review phase of due diligence with Stand-By Systems. EHSI recently executed an option with Stand-By Systems; owner of the new FDA approved SBS 1615 catalytic oxygen generator, as well as the associated LIFEDGE® and MAYDAY® emergency systems. EHSI is currently performing due diligence under this option.

25 May 2010

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Boston Scientific Corporation today announced CE Mark and U.S. Food and Drug Administration approval of its NC Quantum Apex PTCA Dilatation Balloon Catheter. The Company plans to launch the product in European markets this week and in the U.S. next month.

25 May 2010

Overall proportion of hospital patients died after heart attack fell by 37%: AHRQ

The overall proportion of hospital patients who died in the hospital after a heart attack fell by 37 percent between 2000 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The rate fell from from 106 per 1,000 patients to 67 per 1,000 patients during the period

21 May 2010

Lack of discussion on resuming sex after heart attack associated with less sexual activity

Sexual activity declines in the year after heart attack for patients who don't get instructions from their doctors about when it's safe to resume sex, researchers reported at the American Heart Association's 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

21 May 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

A meta-analysis of approximately 80,000 individuals from 32 prospective studies was published in The Lancet on May 1, 2010. The data shows that elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated with an increased risk of coronary heart disease similar in magnitude to that with non-HDL cholesterol or systolic blood pressure.

20 May 2010

Cobalt Pharmaceuticals receives Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets

Watson Pharmaceuticals, Inc. today announced that its subsidiary Cobalt Pharmaceuticals has received a Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets in the 10, 20, 40 and 80 mg strengths. Watson has initiated shipments of this product.

20 May 2010

Significant proportion of men with ED exhibit early signs of CAD: Review

International experts are calling for all men experiencing impotence to undergo thorough medical assessments, after an extensive review showed that a significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Four deaths while waiting in the emergency spur new hospital construction

After the four recent deaths of patients in the emergency department there is a mass attempt to speed up the construction of the Sunshine Coast University Hospital in south-east Queensland.

18 May 2010

30 percent risk of heart attack in Australians over 55

According to a new study researchers have warned that at least one in five Australians over the age of 55 have a 30 percent chance of suffering a potentially fatal heart attack or stroke in the next five years.

18 May 2010

LIFEDGE delivery system from Stand-By Systems ready for pilot scale production

Emerging Healthcare Solutions, Inc. disclosed that the Company has received documents from Stand-By Systems affirming that their revolutionary LIFEDGE prototype is now complete and ready for pilot scale production. EHSI recently executed an option with Stand-By Systems, owner of the new FDA approved SBS 1615 catalytic oxygen generator and associated systems.

18 May 2010

UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems

Researchers will be exploring whether a new, very low cost, one-a-day combined 'polypill' could reduce the risk of heart attacks, strokes and other cardiovascular problems across the world, in a major new international trial that launches today.

18 May 2010

Polypill to be tested in new heart disease trial

17 May 2010

Statins may play role in lowering risk of clot-related diseases: Study

Individuals at risk for clot-related diseases may benefit from taking common cholesterol-lowering drugs known as statins, according to a study conducted by researchers at the University of Connecticut.

17 May 2010

Ambulance fees will deter emergency calls for help and risks lives: Study

Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

Heart Attack News and Research

HDL cholesterol can transform from good to bad actor in heart-disease process

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

Researchers develop new device that can change current landscape of chronic wound management

EHSI reports favorable completion of due diligence with Stand-By Systems

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Overall proportion of hospital patients died after heart attack fell by 37%: AHRQ

Lack of discussion on resuming sex after heart attack associated with less sexual activity

Blood biomarker underscores role of inflammation in vascular disease

Elevated levels of Lp-PLA2 associated with increased risk of coronary heart disease

Cobalt Pharmaceuticals receives Notice of Compliance from Health Canada to market Atorvastatin Calcium Tablets

Significant proportion of men with ED exhibit early signs of CAD: Review

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Four deaths while waiting in the emergency spur new hospital construction

30 percent risk of heart attack in Australians over 55

LIFEDGE delivery system from Stand-By Systems ready for pilot scale production

UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems

Polypill to be tested in new heart disease trial

Statins may play role in lowering risk of clot-related diseases: Study

Ambulance fees will deter emergency calls for help and risks lives: Study

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News